Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | HSD11B1 | P28845 | 10/20 | 0.64 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.61 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.61 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.61 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.61 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.61 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.61 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.61 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GCK | P35557 | 1/20 | 0.56 |
| ▸ | GCKR | Q14397 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3556996 | 1.00 | LMNA (0.68) | LMNAGAAHSD11B1PDK1PDK2 | |
| SCHEMBL3551978 | 1.00 | LMNA (0.68) | LMNAGAAHSD11B1PDK1PDK2 | |
| SCHEMBL24962668 | 0.85 | GCK (0.64) | LMNAGAAPDK1PDK2PDK3 | |
| SCHEMBL29763096 | 0.84 | LMNA (0.76) | LMNAGAAHSD11B1PDK1PDK2 | |
| SCHEMBL11959848 | 0.84 | LMNA (0.76) | LMNAGAAHSD11B1PDK1PDK2 | |
| SCHEMBL24962669 | 0.83 | GCK (0.65) | LMNAGAAPDK1PDK2PDK3 | |
| SCHEMBL3549282 | 0.83 | HSD11B1 (0.59) | LMNAGAAHSD11B1ABCC9ABCC8 | |
| SCHEMBL13036466 | 0.83 | HSD11B1 (0.58) | LMNAGAAHSD11B1ALDH1A1 | |
| SCHEMBL11959899 | 0.83 | HSD11B1 (0.58) | LMNAGAAHSD11B1ALDH1A1 | |
| SCHEMBL9906448 | 0.81 | LMNA (1.00) | LMNAGAAHSD11B1USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753421-B1 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | AMGEN INC (US) | 2012-08-01 | — | — | EP | claimed |
| EP-2243494-A1 | Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist. | OntoChem GmbH (DE) | 2010-10-27 | — | — | EP | claimed |
| US-20090075975-A1 | ARYLSULFONAMIDES AND USES RELATED THERETO | AMGEN INC. | 2009-03-19 | — | — | US | claimed |
| EP-1753421-A2 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | Amgen Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| US-20050288271-A1 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2005-12-29 | — | — | US | claimed |
| WO-2005118538-A2 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | AMGEN, INC. (US) | 2005-12-15 | — | — | WO | claimed |
| EP-1753421-B1 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | AMGEN INC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1753421-B1 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | AMGEN INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-7834047-B2 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834047-B2 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834047-B2 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2010-11-16 | — | — | US | disclosed |
| WO-2010121814-A1 | PHARMACEUTICAL COMPOSITION, COMPRISING A STEROID-DEHYDROGENASE-REDUCTASE INHIBITOR, AND A MINERALOCORTICOID RECEPTOR ANTAGONIST | ONTOCHEM GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
| EP-2243494-A1 | Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist. | OntoChem GmbH (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-20090075975-A1 | ARYLSULFONAMIDES AND USES RELATED THERETO | AMGEN INC. | 2009-03-19 | — | — | US | disclosed |
| US-7495012-B2 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495012-B2 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495012-B2 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1753421-A2 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | Amgen Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20050288271-A1 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2005-12-29 | — | — | US | disclosed |
| WO-2005118538-A2 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | AMGEN, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075975-A1 | ARYLSULFONAMIDES AND USES RELATED THERETO | ARSA, STS, SULT2A1 | LMNA 3143/4885GAA 108/4885HSD11B1 162/4885 |
| US-20050288271-A1 | Arylsulfonamides and uses related thereto | ARSA, STS, SULT2A1 | LMNA 3143/4885GAA 108/4885HSD11B1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.